Business Wire

OSAKA-BUSINESS-DEV-AGCY

15.12.2022 06:01:35 CET | Business Wire | Press release

Share
OBDA-Aiming to create a unicorn company from Kansai that can compete globally! Announcing the Joint Branding of ”Kansai Startup Mashups” From the Three Capitals of Osaka, Kyoto, and Kobe (Hyogo)

The Osaka Business Development Agency, in cooperation with the Keihanshin Startup Ecosystem Consortium and JETRO Osaka, has jointly launched the brand, “Kansai Startup Mashups” to support startups from the Kansai region that are taking on global challenges. From this release and on, we will use "Kansai Startup Mashups" as a branding tool to promote various initiatives for startups in the Kansai region to the global market.
The first event will be held on January 25, 2023, and the call for participants begins today.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005391/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Kansai Startup Mashups in Kobe, 25 / Jan / 2023. (Graphic: Business Wire)

Osaka, Kyoto, and Kobe offer an environment conducive to startups, with a concentration of bio- and healthcare-related companies, Monozukuri (manufacturing), ICT-related companies, as well as universities and research institutes.
Due to its strength environment, the "Osaka-Kyoto-Kobe(Hyogo) Consortium" was selected in 2020 as a global hub city in the Japanese government's strategy to become a world-class start-up hub, and universities, companies, and local governments are working to form an ecosystem of collaboration.

And now, with the aim to further accelerate these efforts, Osaka, Kyoto, and Kobe have jointly launched "Kansai Startup Mashups" as a unified brand for support.
The newly launched "Kansai Startup Mashups" aims to create a world-class startup ecosystem in anticipation of the 2025 Kansai Expo and the post-Kansai Expo, and to create a framework that will lead to the birth of unicorn companies from the Kansai region and the creation and support of startups that will grow to become major players.

In this initiative, the three capitals of Osaka, Kyoto, and Kobe will collaborate to link the circle of cooperation and support among universities, businesses, and government, and to disseminate Kansai startups both domestically and internationally, creating new synergies through the exchange of cutting-edge technology and domestic and international wisdom.
As part of this effort, toward the end of the fiscal year, we will be holding three events under a unified brand; ANCHOR KOBE on Wednesday, January 25, 2023 and engawa KYOTO on February 7, 2023.
On March 2, 2023, a large-scale event will be held at QUINTBRIDGE (Osaka) to unify and communicate the potential of Kyoto, Osaka, and Kobe to become the world's first to realize a future society on the occasion of the Osaka-Kansai Expo.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005391/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release

- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p

Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere

Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release

Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta

Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release

We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi

Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release

Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye